RxDoctor Payments Data

Holly Shinnen

Physician Assistant · Bristow, OKNPI 1891991576

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 100 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$915
  • Lilly USA, LLC$203
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$119
  • Pharmacosmos Therapeutics Inc.$115
  • Amgen$107
  • Boehringer Ingelheim$106
  • plus $94 from 3 others

What the payments were for

  • Food & beverage$1,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,659 in reported general payments places this provider in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$29,525
Medicare patients
162
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$46,127
TrulicityDulaglutide39$37,641
OzempicSemaglutide21$31,257
VraylarCariprazine Hcl21$30,539
GlyxambiEmpagliflozin/Linagliptin15$13,991
Breo ElliptaFluticasone/Vilanterol24$12,712
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,045
Repatha SureclickEvolocumab14$7,900
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,242
Albuterol Sulfate HfaAlbuterol Sulfate69$1,586
Omeprazole70$1,400
Atorvastatin Calcium135$1,337
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,246
Gabapentin72$1,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$106$60,11761 claims
Lilly USA, LLCTrulicity$203$37,64139 claims
AbbVieVraylar$915$30,53921 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$18$25,99947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Bristow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →